In fiscal year 2022, we pledged almost $17.2 million in new grants to 58 exceptional scientists, and provided an additional $1.6 million in stipend increases, extension funding for pandemic-related research delays, and other support.

As we celebrated our 75th anniversary in 2022, we reflected on the transformative impact Damon Runyon's focused and strategic funding has had on cancer treatments. Now, as we move forward, we're knocking on the door of new breakthroughs that might have sounded impossible just a decade ago.